SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending intensely following the FDA approval of YARTEMLEA, its first and only therapy for transplant-associated thrombotic microangiopathy (TA-TMA), a critical condition with no prior approved treatments. The community is buzzing with speculation about the stock's significant undervaluation, potential for a short squeeze, and the possibility of a buyout from Novo Nordisk, building on their existing multi-billion dollar licensing deal.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending significantly following the announcement that Sanofi is acquiring the company for $15.50 per share, a move set to enhance Sanofi's adult immunization portfolio with Dynavax's key vaccine assets. The community is buzzing with discussions about the offer's fairness, with many long-term shareholders expressing frustration over the valuation compared to the stock's historical performance, while others celebrate the substantial immediate gains. This development underscores the continued strategic consolidations within the biotech vaccine sector.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is drawing significant attention after its depression drug failed a Phase 2 study and its SCA treatment received an FDA Complete Response Letter, leading to a company restructuring. Despite these setbacks, substantial insider buying and an intense community focus on highly anticipated data from its epilepsy, obesity, and oncology programs are driving conversations about potential future value. Investors are actively discussing whether the current valuation presents a strategic entry point for its diverse pipeline.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is trending as community discussions compare its interoperability vision and performance against emerging rivals like Keeta, which champions superior throughput and compliance-first architecture for institutional financial flows. Many investors express frustration over ATOM's prolonged price declines, which often overshadow its high staking rewards, amidst ongoing community efforts to redesign its tokenomics for long-term sustainability.

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Mimedx Group Inc

MiMedx Group is trending as recent CMS policy changes are poised to dramatically reshape the advanced wound care market by curbing fraud and prioritizing products with strong clinical evidence. The community is actively debating how these regulations will eliminate many higher-priced competitors, creating a significant market share opportunity for MDXG's proven offerings. Investors are keenly focused on how this shift towards evidence-based reimbursement could drive the company's long-term growth despite initial pricing adjustments.

Sonic is the highest-performing EVM L1, combining speed, incentives, and world-class infrastructure, powering the next generation of DeFi applications. The chain provides 400,000 TPS and sub-second finality.  Sonic's Fee Monetization (FeeM) program rewards developers with up to 90% of the fees their apps generate, adapting the Web2 ad-revenue model to a decentralized framework. Developers now directly profit from their app's traffic and user engagement.  Furthermore, the Sonic Gateway provides developers and users with seamless access to vast liquidity through a native, secure bridge connected to Ethereum. With a unique fail-safe mechanism, it ensures your assets are protected in all circumstances.

Sonic (prev. FTM)

The recent Coinbase listing for Sonic ($S) is a major topic, alongside ongoing community debate surrounding its transition from Fantom (FTM) and upcoming airdrop mechanics. While many express frustration over its recent price performance and the rebrand, a segment of the community views current levels as an accumulation opportunity, anticipating a strong comeback based on its technical capabilities and new developments.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display Technologies, Specialty Materials, Environmental Technologies, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computer, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Environmental Technologies segment focuses on manufacturing ceramic substrates and filter products for emissions control in mobile applications. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning is generating significant buzz following its strong financial performance and optimistic long-term growth projections, largely fueled by surging demand for its optical communications products critical for AI data centers. Community discussion highlights the company's essential role in AI infrastructure and the successful adoption of its Gorilla Glass innovations by major consumer electronics partners, leading many to anticipate further stock appreciation.

RAWW MILK COIN

RAWW MILK COIN is buzzing as its community highlights a year of sustained development and continuous content drops, from new webtoons and "Truth Series" videos to an album and game updates. The sentiment centers on RAWW building a unique "anti-degen" lifestyle and expanding into a full cultural universe, rather than just being a typical meme coin. This consistent delivery, even through market volatility, underscores its distinct philosophy and community-driven longevity.

Inflection Point Acquisition Corp. IV is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Andrew Stephen Gundlach and Michel Combes on June 24, 2024 and is headquartered in New York, NY.

Inflection Point Acquisition Corp. IV - Ordinary Shares - Class A

Bleichroeder Acquisition Corp I

Bleichroeder Acquisition Corp I ($BACQ) is generating significant buzz following multiple bullish reports from Citron Research, highlighting its compelling risk/reward ahead of a merger with Merlin Labs. The community is actively discussing Merlin's advanced AI-enabled autonomous flight technology, substantial defense contracts, and partnerships with major aerospace primes, all seen as strong growth catalysts for the defense tech SPAC. Many view the current valuation favorably due to its perceived limited downside and significant upside potential post-merger.

snowball is the first token in the world that uses the pumpfun creator fees to automatically marketmake itself aggressively.

snowball

SNOWBALL CRYPTO is trending due to community excitement surrounding its innovative script designed to combat "sneaky devs" and prevent "rug pulls," positioning it as a potential "game changer" for new launches on the Solana blockchain. Many users are optimistic about its early-stage potential to foster trust within the market, while some community members advise caution regarding potential pump and dump activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adicet Bio, Inc. (NASDAQ:ACET) Given Average Rating of "Moderate Buy" by Analysts

Shares of Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven brokerages that are covering the firm, Marketbeat.com reports. One...

Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Rating of "Moderate Buy" from Analysts

Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat.com reports...

Adicet Bio's (ACET) "Outperform" Rating Reiterated at Wedbush

Wedbush reiterated an "outperform" rating and issued a $5.00 price target on shares of Adicet Bio in a report on Thursday...

Adicet Bio (NASDAQ:ACET) Releases Earnings Results, Misses Expectations By $0.03 EPS

Adicet Bio (NASDAQ:ACET - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the...

Are Medical Stocks Lagging  Exact Sciences (EXAS) This Year?

Here is how Exact Sciences (EXAS) and Adicet Bio, Inc. (ACET) have performed compared to their sector so far this year.

Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adicet Bio (ACET) Upgraded to Buy: Here's Why

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adicet Bio shares rise on FDA Fast Track Designation for ADI-001

Investing.com -- Adicet Bio shares jumped 6.4% premarket after the company announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its investigational therapy ADI-001 for the treatment of systemic sclerosis (SSc).

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

ACET
Adicet Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACET News

ACETAdicet Bio Inc